Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

John R. Perfect, Kieren A. Marr, Thomas J. Walsh et al. · Clinical Infectious Diseases · 2003 · 675 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

B-J Kullberg, JD Sobel, Markus Ruhnke et al. · The Lancet · 2005 · 522 citations

Life Sciences, Microbiology, Pharmacology +15

Antifungal Susceptibility Survey of 2,000 Bloodstream <i>Candida</i> Isolates in the United States

Luis Ostrosky‐Zeichner, John Rex, Peter G. Pappas et al. · Antimicrobial Agents and Chemotherapy · 2003 · 499 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts

F. Sabatelli, Rutul Patel, Paul A. Mann et al. · Antimicrobial Agents and Chemotherapy · 2006 · 487 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Has Antifungal Susceptibility Testing Come of Age?

John Rex, Michael A. Pfaller · Clinical Infectious Diseases · 2002 · 363 citations

Veterinary Medicine, Infectious Diseases, Pharmacology +15